Technology evaluation: gene therapy (mesothelioma), NCI.
The National Cancer Institute is sponsoring a phase I clinical trial by the University of Pennsylvania involving administration of recombinant adenovirus containing the HSV-tk gene and subsequent tumor kill by ganciclovir, for the gene therapy of malignant mesothelioma. Twenty one patients have been enrolled into the trial.
Banerjee
D
D
Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. banerjed@mskcc.org
D000260:Adenoviruses, Human / Q000235:genetics*; D000740:Anemia / Q000209:etiology; D000075202:Contraindications; D003673:Defective Viruses / Q000235:genetics*; D015774:Ganciclovir / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D015316:Genetic Therapy; D005822:Genetic Vectors / Q000008:administration & dosage / Q000009:adverse effects / Q000235:genetics / Q000627:therapeutic use*; D006801:Humans; D008654:Mesothelioma / Q000188:drug therapy / Q000628:therapy*; D009316:National Institutes of Health (U.S.); D014411:Neoplastic Stem Cells / Q000187:drug effects / Q000201:enzymology / Q000821:virology; D009928:Organ Specificity; D010414:Pennsylvania; D010997:Pleural Neoplasms / Q000188:drug therapy / Q000628:therapy*; D011355:Prodrugs / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D018139:Simplexvirus / Q000201:enzymology*; D013937:Thymidine Kinase / Q000235:genetics*; D016896:Treatment Outcome; D014481:United States; D014495:Universities; D014764:Viral Proteins / Q000235:genetics*
D011355:Prodrugs; D014764:Viral Proteins; D013937:Thymidine Kinase; D015774:Ganciclovir